长按二维码,关注官方公众号
QR Code for the Conference Website (Mobile)
Enter the applet sharing event using WeChat scan.
As the global biopharmaceutical industry enters a new phase of restructuring, 2026 will be a pivotal year for Chinese innovative drug companies to transition from "participants" to "co-builders." At the beginning of the 15th Five-Year Plan, facing multiple challenges such as geopolitical complexities, tightening global regulations, and diverging capital environments, China's biopharmaceutical industry is encountering unprecedented opportunities for transformation.
Under the theme "Connect · Restructure · AI-Powered · Co-Construct," BioCon2026 will focus on core topics such as internationalization strategies, source innovation, technology transfer, and capital pathway reshaping. It will bring together world-renowned scientists, industry leaders, regulatory experts, investment institutions, and innovative companies to discuss how China's biopharmaceutical sector can build a sustainable global development path by leveraging the combined benefits of technological advancement, capital market recovery, and model innovation.
This conference will provide in-depth analysis of the latest advancements and industrialization challenges in cutting-edge technologies such as bispecific antibodies, ADCs, protein vaccines, nucleic acid drugs, in vivo and immune cell therapy, stem cell therapy, and AI-driven drug discovery It aims to build an international exchange platform that is high-level, practice-oriented, and deeply connective.
上海大学医学院副院长 上海大学细胞治疗创新研究院院长 上海细胞治疗研究院院长 上海细胞治疗工程技术研究中心主任 上海吴孟超联合诺贝尔奖获得者医疗科技创新中心主任
Dr. Zhang is the co-founder, president and CEO of AEON(Beijing) a joint venture between Eureka Therapeutics Inc. and Zhongyuan Concorde Cell Gene Engineering Co., Ltd. (SH: 600645). Prior to the establishment of Yiang Biology, Dr. Zhang Yu served as assistant president and senior strategic planning expert of Zhongyuan Concorde Cell Gene Engineering Co., Ltd. (SH: 600645). Dr. Zhang received a bachelor's and master's degree in biomedical engineering from Beijing University of Aeronautics and Astronautics, and a doctor's degree in stem cell and regenerative medicine from Heinrich-Heine-Universit t Dyusseldorf University in Heinrich, Germany. During his stay in Germany, he served as a director of the Rhine Forum in Germany, a lecturer at the Rhine University of Science and Technology in Bonn, Germany, a visiting scholar at the Helmholtz Center of the German Space Agency and the University of Palermo in Italy. Dr. Zhang is a member of the German Stem Cell Society, the Chinese Society of Cell Biology and a reviewer of Current Stem Cell Research & Therapy magazines. Selected 131 talents plan, the first batch of Tianjin Green Card winners.
张翱，上海交通大学特聘教授，博士生导师，研究组长。2000年在中科院上海有机化学研究所博士毕业，2001-2004年分别在美国乔治敦大学医学中心和哈佛医学院进行博士后研究，2004-2006年担任哈佛医学院讲师。2006年入选中科院“百人计划”回国加盟上海药物研究所，入选上海市浦江人才计划和上海市优秀学科带头人计划，2011年获国家杰出青年科学基金，领衔的研究团队获2018年度科技部“创新人才推进计划”-“重点领域创新团队”称号，2019年获中组部国家“万人计划”领军人才。2020年加入上海交通大学药学院。张翱教授研究团队主要致力于药物化学技术创新推动的新药发现研究，尤其是聚焦基于天然产物的药物化学和化学生物学研究、难靶蛋白的药物设计、分子靶向个性化药物研究等领域。已发表J Am Chem Soc, Angew Chem Int Ed, Chem Sci, J Med Chem，Chem Rev, Pharmacol & Ther等SCI论文170余篇，申请国内国际专利60余项。主持研发的3个1类新药已经进入临床试验研究，多个候选新药正在进行临床前研究。
钱程，重庆精准生物技术有限公司首席科学家、重庆大学肿瘤医院精准医学研究中心主任，国家精准医学生物治疗国际联合研究中心主任、科技部重点研发计划首席科学家，中国医药质量管理协会精准生物治疗专委会主任委员，重庆市抗癌协会生物治疗专委会主任委员。长期致力于癌症发生的分子机制及免疫细胞治疗癌症的基础和临床应用研究以及产品的开发，在肿瘤生物治疗和干细胞治疗方面，做出了突出的成绩。所获得的研究成果在国际著名的Journal of Clinical Oncology、Gastroenterology、Hepatology等SCI期刊上发表论文170余篇，总影响因子达1000, 他引10000余次。获得PCT国际发明专利10项。目前，其带领的研究团队，主要从事肿瘤CAR-T细胞治疗的基础、转化和临床应用。
Founded in 2014, BioCon has accompanied biopharmaceutical professionals through 12 years of growth. Originating in Wuhan, it has since been held in Shanghai, Hangzhou, and Beijing. Over the past 12 years, it has become one of the longest-standing biopharmaceutical brand annual conferences in China, witnessing the entrepreneurial journeys of the earliest cohort of returnees and consistently supporting the growth and development of China's biopharmaceutical industry.
To date, BioConChina has engaged over 36,000 senior professionals from the global biopharmaceutical industry, with more than 910 leading service and product suppliers participating as sponsors, and a total of over 1,500 industry leaders contributing as expert speakers and panelists.
